Actinium Pharma (ATNM) Announces Actimab-MDS and Planned Phase 2 Trial in Myelodysplastic Syndromes Targeted at Patients with High-Risk p53+ Genetic Mutations
Tweet Send to a Friend
Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced Actimab-MDS, a new clinical initiative focused on myelodysplastic syndrome or MDS. Actimab-MDS ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
